CSI Market
Sign In | Register

Regulus Therapeutics Inc (RGLS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RGLS Annual Cash Flow →
Examining cash flow movements between Regulus Therapeutics Inc and Mar 31 2024 reveals how Mar 31 2025 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2025)
3 Months 		(Dec 31 2024) (Sep 30 2024) (Jun 30 2024) (Mar 31 2024)
Operating Activities
Income-9.63
Depreciation & amortization0.09
Amortization of Other Assets-0.20
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation2.25
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Net Amortization Of Premiums On Investment Securities-
Gain Loss From Valuation Of Convertible Note Payable-
Increase Decrease In Accrued Expenses-
Increase Decrease Operating Lease Liabilities-
Operating Lease Right Of Use And Lease Liabilities Net Gain Loss-0.18
Gain Loss On Loan Forgiveness-
Increase Decrease In Accrued Research And Development Expenses0.38
Income taxes0.00
Gain (Loss) on Investments0.00
Increase (Decrease) in Employee Related Liabilities-2.45
Increase (Decrease) in Accounts Payable-0.75
Increase (Decrease) in Accrued Liabilities-0.21
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.02
Other Working Capital0.07
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-10.61
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale of Short-term Investments21.50
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds Payments from Sale and Acquisition of Property Plant and Equipment Net-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities21.50
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.05
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-38.59
Net Proceeds From Issuance Of Convertible Notes Payable-
Proceeds From Capital Lease Financing-
Proceeds From Finance Leases-
Paymentson Finance Leases-
Payments For Finance Leases-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents38.59
Proceeds From Federal Program-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.05
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-10.61
Total Cash Flow10.93
4 historic quarters locked

Sign in to unlock the full Regulus Therapeutics Inc cash flow history.

Sign In Create Free Account

About Regulus Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-25-023872

Figures are derived from filed reports and may be restated. Historical data is subject to revision.